Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 285

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 285
---
 ) |     |       |   (1 | ) |
| Closing impairment allowance                     |     |              |   54 |   |     |       |  120 |   |

The impairment allowance is based on assumptions around probability of default, loss given default, exposure at default and the discount rate. Judgment is used in making these assumptions and selecting the inputs to the expected credit losses calculation, based on any historical experience and current market conditions, as well as forward looking estimates at the end of the reporting period. Interest rate risk Interest rate risk is the risk of a change in the price of a financial instrument due to fluctuations in interest rates, leading to a financial loss. The Group is exposed to interest rate risk on its marketable securities. Although the bonds pay interest at a fixed rate, the value of the Group’s marketable securities would decrease in the short term in the event of an interest rate increase in alternative investments. As of December 31, 2024, if interest rates had increased / decreased by 50basis points, with all other variables held constant, the Group’s total comprehensive loss would have been $ 0.3million higher / lower (2023: $ 0.7million higher / lower), due to the movement in the fair value of the Group’s marketable securities. Liquidity risk Liquidity risk is the risk that the Group may not be able to generate sufficient cash resources to settle its obligations in full as they fall due or can do so only on terms that are materially disadvantageous. Prudent liquidity risk management implies maintaining sufficient cash to cover working capital requirements. Cash is monitored by the Group’s management. Funding and liquidity risks are reviewed regularly by the Board of Directors and management. The Group funds its capital requirements through capital raising. All financial liabilities, aside from lease liabilities as included in Note 14 “Leases”, are due within one year from the balance sheet date. Capital management The Group considers capital as equivalent to the IFRS equity on the balance sheet (including share capital, additional paid-in capital and all other equity reserves attributable to the owners of the Company). The Group has no interest-bearing debt. The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern and to provide returns to its shareholders through advancing our investigational pharmaceutical product candidates towards regulatory approval. Fair value estimation The carrying amount is considered to be a reasonable approximation of fair value for the following financial assets and liabilities:

| ● | Cash |

| ● | Other current assets |

| ●